Events

World Adopt Summit 2017

July 25, 2022

March 7-9, 2017 – London, United Kingdom
Targeting the “Untargetable” Solid Tumor Antigens

ASH Annual Meeting

July 25, 2022

December 3-6, 2016 – San Diego, CA
Anti-CD19-ARTEMIS” T cell therapy reduces cytokine release without compromising efficacy against preclinical lymphoma models

CAR-TCR Summit

July 25, 2022

September 13-16, 2016 – Boston, MA
TCR-like CARs targeting intracellular cancer-specific antigens for treatment of solid tumors

CBIS 11th Biennial Conference

July 25, 2022

July 29-August 2, 2016 – Chengdu, China
Innovating antibody and adoptive T-cell therapies for targeting undruggable cancer antigens

ASCO

July 25, 2022

June 3-7, 2016 – Chicago, IL
Towards a safer CD19 CAR-T therapy with reduced risk of Cytokine Release Syndrome (CRS)

AACR

July 25, 2022

April 16-20, 2016 – New Orleans, LA
ET1402L1-CAR-T therapy targeting alpha-fetoprotein (AFP)-MHCI complex for liver cancer

CAR-T Summit

July 25, 2022

November 12-13, 2015 – Cambridge, MA
First-in-class CAR-T therapy for HCC via targeting an AFP-MHCI complex

Alexa Willson

CFO

Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.

Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.

Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.